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Abstract
Prior information is often incorporated informally when planning a clinical trial.
Here, we present an approach on how to incorporate prior information, such as
data from historical clinical trials, into the nuisance parameter based sample size
re-estimation in a design with an internal pilot study. We focus on trials with con-
tinuous endpoints in which the outcome variance is the nuisance parameter. For
planning and analyzing the trial frequentist methods are considered. Moreover, the
external information on the variance is summarized by the Bayesian meta-analytic-
predictive (MAP) approach. To incorporate external information into the sample
size re-estimation, we propose to update the MAP prior based on the results of the
internal pilot study and to re-estimate the sample size using an estimator from the
posterior. By means of a simulation study, we compare the operating character-
istics such as power and sample size distribution of the proposed procedure with
the traditional sample size re-estimation approach which uses the pooled variance
estimator. The simulation study shows that, if no prior-data conflict is present,
incorporating external information into the sample size re-estimation improves the
operating characteristics compared to the traditional approach. In the case of a
prior-data conflict, that is when the variance of the ongoing clinical trial is unequal
to the prior location, the performance of the traditional sample size re-estimation
procedure is in general superior, even when the prior information is robustified.
When considering to include prior information in sample size re-estimation, the
potential gains should be balanced against the risks.
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1 Introduction
In clinical trials with a continuous outcome variable, the sample size planning is often
based on the assumption of normally distributed data. In this case, the sample size is
affected by the outcome variance and the assumed treatment effect size as well as the
type I and type II error rates. When planning the sample size, the treatment effect size
is generally determined based on clinical relevancy and the type I and type II error rates
are selected from a set of agreed upon values. However, the outcome variance is usually
unknown and determining it to calculate the sample size has been discussed extensively
in literature. If historical trials with designs similar to the planned trial are available, the
variance for the sample size formula can be estimated from the historical trials. [1–4] An-
other possibility to obtain an estimate of the outcome variance is from a pilot study. Pilot
studies can either be internal or external, the difference being that internal pilot studies
are part of the main clinical trial and external pilot studies are a separate entity. [5] The
variance estimate or a confidence limit of the variance obtained from an external pilot
study can be considered for the sample size planning of a clinical trial. [6–8] However, there
is no guarantee that the outcome variance of a clinical trial corresponds to the estimate
obtained from an external source. For situations in which information on the variance
is uncertain, it has been proposed to include an internal pilot study into the design of a
clinical trial and to re-estimate the outcome variance (or nuisance parameters in general),
and thus the sample size of the ongoing clinical trial, based on the results of the internal
pilot study. [5] Nuisance parameter based sample size re-estimation in clinical trials has
been studied extensively and we refer to reviews for a detailed recapitulation. [9–12] It is
worth emphasizing that nuisance parameter based sample size re-estimation can be per-
formed either blinded or unblinded, in contrast to effect based sample size re-estimation,
which is always performed unblinded. For a comparison of effect based versus nuisance
parameter based sample size re-estimation and the respective operational and regulatory
challenges, we refer to existing literature. [12,13]
In this manuscript we focus on two-arm parallel group superiority trials with nor-
mally distributed endpoints planned and analyzed using frequentist methods. We assume
that the clinical trial design includes an internal pilot study with a nuisance parameter,
that is the outcome variance, based sample size re-estimation. Moreover, we also assume
that prior information on the outcome variance is available as a meta-analytic-predictive
(MAP) prior. [3] We study several methods to incorporate prior information on the out-
come variance into the unblinded sample size re-estimation and assess the power and
final sample size distribution of the respective sample size re-estimation procedures in a
simulation study. We focus on re-estimating the sample size such that the clinical trials
maintains a prespecified power. Our motivation for primarily focusing on incorporating
information into the sample size re-estimation based on unblinded data instead of blinded
data is of a computational nature. We then elaborate on why the findings for unblinded
data are qualitatively the same as for incorporating information into the sample size re-
estimation based on blinded data. Incorporating prior information into the sample size
re-estimation has already been proposed for binomial data in the early 1990s but not
studied intensively. [14] More recently, Hartley introduced an approach to blinded sample
size re-estimation for normal data. [15]
This manuscript is structured as follows. In Section 2 we elaborate the statistical
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model and recapitulate MAP priors as well as how to incorporate external information
into the sample size planning. In Section 3 we propose several procedures for incorpo-
rating prior information into the sample size re-estimation. Clinical trial examples are
discussed in Section 4. The performance characteristics of the introduced sample size re-
estimation procedures incorporating prior information are studied in Section 5. In Section
6 we discuss how prior information can be incorporated into the sample size re-estimation
with blinded data and why the performance of the resulting procedures are qualitatively
identical to the performance of the procedures based on unblinded data. We conclude
with a discussion in Section 7.
2 Statistical model and meta-analytic-predictive pri-
ors
This section is split into three parts. In the first part we outline the statistical model con-
sidered in this manuscript and the classical frequentist approach of sample size planning.
In the second part we recapitulate MAP priors. In the third part several approaches for
incorporating prior information into frequentist sample size planning are discussed.
2.1 Statistical model
Here we consider a two-arm parallel group superiority trial with normally distributed
endpoints. More precisely, let Xij be the random variable modeling observation j =
1, . . . , ni in group i = T, C. Here, i = T indicates the treatment group and i = C the
control group. The randomization ratio is given by k = nC/nT and the total sample size
is given by n = nT + nC . The random variables are independently normally distributed
given the group mean µi and the variance σ
2, i.e.
Xij |µi, σ2 ∼ N
(
µi, σ
2
)
.
Larger values of µi, i = T, C, are considered to be more desirable. We focus on the
frequentist hypothesis testing problem
H0 : µT ≤ µC vs. H1 : µT > µC .
The most common test for the hypothesis H0 is the two-sample Student’s t-test with test
statistic
T =
X¯T − X¯C
σˆ
√
1
nT
+ 1
nC
.
The sample standard deviation σˆ is the square root of the pooled sample variance. The
null hypothesis H0 can be rejected if the test statistic T exceeds tn−2,1−α, the (1 − α)-
quantile of a t-distribution with n−2 degrees of freedom. Under the alternative hypothesis
H1, the test statistic T follows a noncentral t-distribution with n− 2 degrees of freedom
and noncentrality parameter
λ =
δ
σ
√
1
nT
+ 1
nC
=
√
nk
k + 1
δ
σ
.
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Thus, the power of Student’s t-test can be expressed as a function B(n, σ2, δ, k) of the
sample size n, the variance σ2, the effect size δ, and the ratio k = nC/nT , i.e.
B(n, σ2, δ, k) = P (T ≥ tn−2,1−α) = 1− Fnct (tn−2,1−α;λ, n− 2)
with Fnct (· ;λ, ν) the cumulative distribution function of a noncentral t-distribution with
noncentrality parameter λ and ν degrees of freedom. The total sample size n to test the
hypothesis H0 with a prespecified nominal power of 1− β is given by
n = min
{
n˜ ∈ N : Fnct (tn˜−2,1−α;λ∗, n˜− 2) ≤ β; λ∗ =
√
n˜k
δ∗
σ(k + 1)
}
. (1)
Here, δ∗ > 0 is the assumed effect size under the alternative hypothesis. Especially for
large sample sizes, closed form approximations of the above sample size formula based on
normal quantiles or quantiles of Student’s t-distribution exist and are commonly applied
in practice.
2.2 Meta-analytic-predictive priors
Planning the sample size of a trial based on (1) requires knowledge about the variance σ2.
In practice, information about the variance σ2 is often gathered from historical studies.
Schmidli et al. formalized information gathering for nuisance parameters based on the
meta-analytic-predictive (MAP) approach. [3] In the following, we give a brief introduction
to the MAP approach for variances. The idea is to perform a random effects meta-
analysis using a normal Bayesian hierarchical model for the logarithm of the variance.
The resulting posterior predictive distribution for the variance is the MAP prior which
is used to predict the variance of a new clinical trial. In detail, let j = 1, . . . , J be the
index for J historical clinical trials and let σˆ2j be the sample variance and νj the respective
degrees of freedom. The unknown true variance of trial j = 1, . . . , J is denoted by σ2j .
Considering that we are focusing on clinical trials with normal data, we assume that the
sample variances follow a χ2-distribution in the sense
νj
σ2j
σˆ2j
∣∣∣∣σ2j ∼ χ2νj .
We note that the χ2-distribution is a special case of the Gamma distribution and it follows
that
σˆ2j
∣∣∣σ2j ∼ Gamma
(
0.5νj , 0.5
νj
σ2j
)
.
A random variable following a Gamma distribution with shape parameter a and rate
parameter b, Gamma(a, b), has mean a/b and variance a/b2. To gather information about
the variance σ2new of a new, to be planned clinical trial from the variances of historical
clinical trial, the variance σ2new and the variances σ
2
j of historical clinical trials have to be
linked. As it is common in random effects meta-analyses, we assume that the variances
origin from the same distribution. Here, we assume that the log-transformed variances
θnew = log(σ
2
new), θ1 = log(σ
2
1), . . . , θJ = log(σ
2
J) are independent and identically normally
distributed,
θnew, θ1, . . . , θJ ∼ N
(
µ, τ 2
)
.
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The random effects meta-analysis can be performed using a Bayesian hierarchical model.
Thereto, prior distributions for the mean µ and the between-trial standard deviation
τ have to be selected. Common choices are weakly informed priors such as a normal
distribution with a large variance for the mean and a half-normal distribution for the
standard deviation. [3] The posterior density p(µ, τ, θnew|σˆ21, . . . , σˆ2J) cannot be calculated
analytically. However, through Markov chain Monte Carlo (MCMC) computations ran-
dom samples of the parameter vector (µ, τ, θnew) can be generated. The random numbers
for θnew can then be transformed to obtain random numbers for the posterior predictive
distribution of the variance of a new trial σ2new. The posterior predictive distribution of
σ2new is the MAP prior for the variance. The MAP prior for the variance generally does
not have a closed form expression but, just like every prior distribution, it can be ap-
proximated by a mixture of conjugated priors. [16] For the sake of convenience, the prior
of the precision ωnew = 1/σ
2
new, and not the prior of the variance σ
2
new, is approximated
by a mixture of conjugated priors. For a normal model, the conjugated prior of the preci-
sion is the Gamma distribution. Therefore, in this manuscript we assume that the prior
distribution for the precision ωnew = 1/σ
2
new is a mixture of Gamma distributions
ωnew ∼
L∑
l=1
wl Gamma(al, bl).
When approximating the MAP prior, the parameters wl, al, and bl are obtained by calcu-
lating the maximum-likelihood estimators from the MCMC random sample of the trans-
formation 1/ exp(θnew). The number of mixture components L is chosen such that the
resulting fitted mixture distribution approximates the MCMC random sample with the
desired precision. No closed form expression for the maximum-likelihood estimators exists,
but literature on their numerical calculation is available. [17] For details on the method-
ological background of the MAP approach and its use to summarize historical information
on the variance, we refer to Schmidli et al. [3,19] Since ωnew follows a mixture of Gamma
distributions, the variance σ2new follows a mixture of inverse Gamma distributions with
the same weights, shape parameters, and rate parameters. An inverse Gamma distributed
random variable with shape parameter a and rate parameter b, InvGamma(a, b), has mean
b/(a− 1) and variance b2/((a− 1)2(a− 2)).
The MAP prior for the variance might mismatch the variance observed in a new clini-
cal trial, i.e. a prior-data conflict can be present. More precisely, a prior-data conflict can
for example be defined as the case when the observed variance is outside a 95% probabil-
ity interval of the prior-predictive distribution, similar to Box (1980). [18] Schmidli et al.
introduced a robustified version of MAP priors which aims to mitigate the risk of a prior-
data conflict. [19] We briefly recapitulate their robustification of MAP priors. Thereto,
let pMAP (·) be the MAP prior obtained from historical data and let pV (·) be a vague
conjugate prior. Moreover, let wR be the prior probability of a prior-data conflict. Then,
a robustified MAP prior with density prMAP (·) is the mixture distribution of the MAP
prior and the vague conjugate prior with mixture probability wR, that is
prMAP (x) = wR pV (x) + (1− wR)pMAP (x).
The choice of the prior probability wR of a prior-data conflict reflects the initial infor-
mation of how likely a prior-data conflict is. In this sense, the choice of wR has to be
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made on a case-to-case basis based on the available information and, for instance, on the
desired operating characteristics of the resulting robustified prior. An example in which
the prior information for the nuisance parameter was robustified during the sample size
planning of a clinical trial was discussed by Schmidli et al. [3] Moreover, it is also important
to emphasize that the prior probability wR of a prior-data conflict gets updated when the
posterior distribution is calculated.
2.3 Sample size planning based on prior information on the nui-
sance parameter
In the following we outline how prior information on the nuisance parameter can be
incorporated into the frequentist sample size calculation of a clinical trial. The methods for
including prior information on the nuisance parameter into the sample size re-estimation,
which we will present in the next section, follow the same principles. To plan the sample
size n of a new trial based on the MAP prior pσ2(·) of the variance σ2, a Bayes estimator of
σ2 can be plugged into Formula (1). [3] There are various ways of defining a Bayes estimator;
in this sense, Bayes estimators are not unique. [20] Here, we focus on the mean σˆ2mean and
the median σˆ2med of the MAP prior which minimize the squared error risk and the absolute
deviation, respectively. The sample size can also be planned based on prior information
on the standard deviation σ or on the precision ω = 1/σ2. However, if the Bayes estimator
is not transformation invariant, the resulting sample size will differ from the sample size
based on prior information on the variance. When the sample size is determined based
on a location parameter of the MAP prior, the uncertainty of the prior information is not
considered in the planning process. Alternative approaches which consider the variability
of the prior information can either choose percentiles of the MAP prior in Equation (1)
or base the sample size on the unconditional power. The unconditional power concerning
σ2 is the function
B˜(n, δ, k) =
∫
B(n, x, δ, k)pσ2(x)dx.
The total sample size n for testing the hypothesis H0 which is then defined by
n = min
{
n˜ ∈ N : B˜(n˜, δ∗, k) ≥ 1− β
}
. (2)
It is worth emphasizing that the sample size obtained from the unconditional power
generally differs from the sample size obtained with Formula (1).
3 Nuisance parameter based sample size re-estima-
tion using MAP priors
In this section we briefly summarize the general idea of adjusting the sample size based
on an estimate of the nuisance parameter in designs with internal pilot study and then
propose methods which incorporate prior information on the variance in the form of MAP
priors into the sample size re-estimation. As the name implies, in nuisance parameter
based sample size re-estimation, the sample size is altered after the internal pilot study
based on an estimate of the nuisance parameter. The estimation of the nuisance parameter
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can either be done based on blinded or unblinded data. According Section 4.4 of ICH
guideline E9, it must be addressed whether and how the blindness during the sample size
re-estimation was maintained. [21] Other regulatory publications recommend to perform the
nuisance parameter based sample size re-estimation blinded whenever possible, such as a
reflection paper by the Committee for Medicinal Products for Human Use (CHMP). [22]
The recommended method for nuisance parameter based sample size re-estimation in two-
arm parallel group trials with continuous data is the blinded one-sample variance estimator
which estimates the unknown variance by the sample variance of the blinded data. [23–25]
The one-sample variance estimator results in a sample size re-estimation procedure which
meets the power and controls the type I error rate for practically relevant internal pilot
study sizes. Although the one-sample variance estimator is the recommended method for
nuisance parameter based sample size re-estimation, we first introduce the sample size
re-estimation incorporating prior information for unblinded data. The primary reason is
that unblinding of the internal pilot study leads to closed form expressions for the sample
size re-estimation incorporating external information. We will show in Section 6 that the
performance of the sample size re-estimation procedure incorporation prior information
based on blinded data is qualitatively the same as for the procedure relying on unblinded
data. Altering the sample size of an ongoing clinical trial based on unblinded data from
an internal pilot study has first been proposed by Wittes et al. [5] In detail, the idea is to
perform an internal pilot study of size n1, with n1T and n1C denoting the group specific
sample sizes within the internal pilot study. After the outcome measure of the n1 patients
is obtained, the pooled variances σˆ21,pool from the unblinded data is calculated. The sample
size is then re-estimated based on the estimate σˆ21,pool using Equation (1). Let nˆreest denote
the re-estimated sample size. Here, we consider the final sample size of the clinical trial
to be the maximum of the re-estimated sample size and the internal pilot study sample
size, i.e. nˆfinal = max{nˆreest, n1}. [26] Alternatively, the final sample size can be set to
be the maximum of the initially planned sample size and the re-estimated sample size
in which case the sample size re-estimation would not be able to reduce the initially set
sample size. [5] In the case of constrained resources it can also be reasonable to additionally
include an upper limit for the final sample size. [14] Sample size re-estimation based on the
pooled sample variance is able to adjust for a misspecified variance during the planning
of the clinical trial if the internal pilot study is reasonably sized. [5,26,27] This sample size
re-estimation approach inflates the type I error rate and due to the unblinding might
trigger the need of an Independent Data Monitoring Committee (IDMC) to preserve the
blindness of the study personnel. It is worth mentioning that the type I error rate inflation
can be minimized when a bias correction is applied to the variance estimator in the test
statistic at the end of the trial. [28] We do not apply this bias correction here because it
qualitatively does not change the performance of the sample size re-estimation procedure
incorporating prior information.
When the sample size of a clinical trial is planned utilizing prior information or in
general when prior information on the nuisance parameter is available, it seems intuitive
to incorporate said prior information into the sample size re-estimation. We propose to
incorporate prior information on the nuisance parameter into the sample size re-estimation
by updating the prior using the data from the internal pilot study and then re-calculating
the sample size with (1) based on a Bayes estimator of the variance obtained from the
posterior distribution. In more detail, letXij be the random variable modeling observation
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j = 1, . . . , n1i in group i = T, C after the internal pilot study and let ω = 1/σ
2 be the
precision. The prior information on the parameters (µT , µC , ω) is characterized by the
prior density p(µT , µC , ω). Thus, for the posterior density after the internal pilot study
holds
p
(
µT , µC , ω|X¯1T , X¯1C , σˆ21,pool
)
∝ p
(
X¯1T , X¯1C , σˆ
2
1,pool|µT , µC, ω
)
p(µT , µC, ω).
Here, X¯1T , X¯1C , and σˆ
2
1,pool denote the sample mean in the treatment group, the sample
mean in the control group, and the pooled sample variance, respectively, obtained from
the unblinded data of the internal pilot study. In this manuscript we focus on the specific
case of an improper uniform prior for the means which is a prior independent of the prior
for the precision,
p(µT , µC) = p(µT )p(µC) = 1,
p(µT , µC , ω) = p(µT , µC)p(ω).
As mentioned in the previous section, we assume that the precision ω has a mixture of
Gamma distributions as the prior. In the assumed model, this prior distribution is a
conjugate prior and thus the marginal posterior for the precision is again a mixture of
Gamma distributions, [29]
ω
∣∣∣X¯1T , X¯1C , σˆ21,pool ∼
L∑
l=1
w∗l Gamma
(
al +
n1 − 2
2
, bl +
n1 − 2
2
σˆ21,pool
)
.
The updated weights w∗l are given by
w∗l =
rl∑L
l=1 rl
where the single components rl are calculated by
rl = wl
Γ (al + 0.5(n1 − 2))(
bl + 0.5(n1 − 2)σˆ21,pool
)al+0.5(n1−2) b
al
l
Γ(al)
.
Thus, the posterior for the variance σ2 follows a mixture of inverse Gamma distributions.
We denote the mean and the median of the posterior distribution of σ2 as σˆ21,mean and
σˆ21,med, respectively. The mean σˆ
2
1,mean of the posterior distribution is the weighted mean
of inverse Gamma distributions,
σˆ21,mean =
L∑
l=1
w∗l
bl + σˆ
2
1,pool(n1 − 2)/2
al + (n1 − 2)/2− 1 .
The median of an inverse Gamma distribution and the median of a mixture of inverse
Gamma distributions do not have closed form expressions and must be calculated itera-
tively. The re-estimated sample size nˆreest is obtained through (1) by plugging in a Bayes
estimator for the variance. Analogously to the planning of a clinical trial, the sample size
can also be determined by means of the unconditional power, confer (2), or by plugging
in percentiles of the posterior distribution into (1).
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4 Clinical trial examples
In this section we discuss two examples in which we gather information on the vari-
ance from historical clinical trials and predict the variance of a new trial using the
meta-analytic-predictive approach. Then, we study how the prior information about
the variance affects the re-estimated sample size when incorporated into the sample size
re-estimation.
4.1 St John’s wort for major depression
The first example focuses on the use of St John’s wort for major depression. Linde
et al. published a meta-analysis summarizing the effects of St John’s wort for major
depression for a variety of endpoints. [30] Here, we focus on the Hamilton Rating Scale
for Depression (HAMD) score after four weeks of treatment. [31] In Analysis 2.3 of their
review, Linde et al. summarize the results of eleven trials comparing hypericum (St John’s
wort) versus placebo. From the reported results we obtain a pooled variance estimator
and the respective number of degrees of freedom for each trial. The MAP prior for the
precision and, thus, the variance is obtained through a Bayesian meta-analysis of the
sample variances as outlined in Section 2.2. The MAP prior of the precision ω = 1/σ2
can be approximated by the following Gamma mixture distribution
0.16Gamma(4.6, 140.4) + 0.84Gamma(18.2, 689.3).
The prior effective sample size can be calculated as the product of the degrees of free-
dom of the historical trials multiplied by the ratio of the predictive variance assuming no
between-trial heterogeneity and the predictive variance accounted for between-trial het-
erogeneity. [32] Here, this leads to an prior effective sample size of ESS = 24. Table 1 list
characteristics of the MAP priors. Table 1 highlights that the prior information on the
Table 1: Summaries of the MAP priors for the variance σ2, the standard deviation σ, and
the precision ω.
Parameter Mean SD Median 2.5% quantile 97.5% quantile
σ2 39.56 12.56 37.93 21.11 68.52
σ 6.22 0.93 6.16 4.59 8.27
ω 0.0276 0.0097 0.0267 0.0146 0.0474
outcome variance is quite uncertain. In the following we study how the prior information
affects the sample size when incorporated into the sample size re-estimation. Thereto, we
assume internal pilot study sizes of n1 = 25, 75, 125 and that the sample size re-estimation
is performed with an assumed effect of δ∗ = 2.515 which corresponds to a standardized
effect of about 0.4 for a variance of σ2 = 39.56. For this parameter combination, the fixed
design sample size would be n = 198. In Figure 1 the re-estimated sample size is plotted
against the pooled sample variance σˆ2pool obtained from the internal pilot study. Figure
1 shows that the re-estimated sample sizes based on the Bayes estimators, that are the
9
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Figure 1: Re-estimated sample size for the unblinded sample size re-estimation based on
the pooled variance σˆ2pool and for the sample size re-estimation incorporating prior infor-
mation based on the posterior mean σˆ2mean and on the posterior median σˆ
2
med, respectively.
posterior mean and the posterior median, are not increasing as steep as the re-estimated
sample size based on the pooled sample variance. Moreover, the difference between the
re-estimated sample sizes with and without incorporated prior information decreases as
the internal pilot study sample size n1 increases. In other words, the influence of the prior
information on the re-estimated sample size decreases as the internal pilot study sample
size increases.
4.2 Interventions for controlling blood pressure
To improve the blood pressure control of hypertensive patients a variety of interventions
such as self-monitoring, patient education, health care provider education, appointment
reminders, etc. have been proposed. In a meta-analysis, Glynn et al. summarized the
available literature on the effect of various interventions on the blood pressure. [33] In our
example, we focus on the reported results about the systolic blood pressure for patients
who self-monitored their blood pressure, confer Analysis 1.1 in Glynn et al. [33] With
the reported sample variances, we proceed as in the previous example: we calculate a
pooled variance for each study and then perform an Bayesian meta-analysis for the sample
variances. The mixture of Gamma distributions
0.29Gamma(10.28, 2298.63) + 0.71Gamma(38.46, 9366.28).
approximates the MAP prior of the precision ω = 1/σ2. The effective sample size is
ESS = 41. Summary statistics of the MAP priors of the variance, standard deviation,
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Table 2: Summaries of the MAP priors for the variance σ2, the standard deviation σ, and
the precision ω.
Parameter Mean SD Median 2.5% quantile 97.5% quantile
σ2 251.47 58.24 244.7 157.8 385.7
σ 15.76 1.76 15.64 12.56 19.64
ω 0.0042 0.00094 0.0041 0.0026 0.0063
and the precision are listed in Table 2. Analogously to the first example, we study how
the prior affects the re-estimated sample size. As before, the internal pilot study sample
sizes are assumed to be n1 = 25, 75, 125 and the assumed effect is again chosen such that a
standardized effect of 0.4 is obtained for the prior mean of the variance, hence δ∗ = 6.343.
The sample size in a fixed sample design would be n = 198. The results shown in Figure
n1= 25 n1= 75 n1= 125 
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Figure 2: Re-estimated sample size for the unblinded sample size re-estimation based on
the pooled variance σˆ2pool and for the sample size re-estimation incorporating prior infor-
mation based on the posterior mean σˆ2mean and on the posterior median σˆ
2
med, respectively.
2 are qualitatively the same as in Figure 1. However, since the prior effective sample size
is larger in the second example, the difference between the re-estimated sample sizes from
the methods with and without incorporated prior information is larger, too.
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5 Performance of the proposed sample size re-esti-
mation procedure
The most important operating characteristic of a sample size re-estimation procedure is
whether the test at the end of the study meets the target power under the condition
that the type I error rate is controlled under the null hypothesis. Further operating char-
acteristics are the distribution of the final sample size and the type I error rate. In the
following we assess the performance of Student’s t-test for the hypothesis H0 at the end of
the study after the sample size has been altered mid-study using the re-estimation proce-
dure which incorporates prior information. The performance assessment is conducted by
means of a Monte Carlo simulation study. The simulation study is split into three parts.
We start by considering an ideal setting in which the prior information is correct, in other
words no prior-data conflict exists. This is simulated by choosing the expected value of
the prior identical to the true variance σ2 of the clinical trial. Afterwards, we study the
performance of the sample size re-estimation procedure for a prior-data conflict, which is
simulated by choosing the expected value of the prior distribution considerably different
to the true variance σ2 of the clinical trial. We conclude with scenarios which include
a prior-data conflict but in which the prior distribution was also robustified. Particular
emphasis will be placed on the comparison of the sample size re-estimation procedure
incorporating prior information with the sample size re-estimation approach based on
the pooled variance. Several methods for determining the sample size given a prior dis-
tribution were discussed in the previous section. During the presentation of the results
of the simulation study we restrict ourselves to sample sizes re-estimated based on the
Bayes estimators σˆ2mean and σˆ
2
med and do not include sample size re-estimation based on
the unconditional power concerning σ2 or on quantiles of the posterior distribution. The
performance is qualitatively the same with respect to the effects of the prior effective sam-
ple size, the internal pilot study, and the prior-data conflict and therefore not presented
here. Throughout this section, we select a Gamma distribution, not a mixture of Gamma
distributions, as the MAP prior for the precision ω. This simplified setting is already
sufficient to highlight the main characteristics of the sample size re-estimation procedure
incorporating prior information while not artificially increasing the number of parameters.
Moreover, the effective sample size can be illustrated easily for a Gamma distribution.
The prior effective sample size for a Gamma distribution with shape parameter a and
rate parameter b is given by ESS = 2a. Table 3 lists the parameters considered in the
simulation study. As listed in Table 3, the true variance of the normally distributed data
is σ2 = 1. We assume a mean difference in the alternative of δ∗ = 0.5. For σ2 = 1 and
δ∗ = 0.5, in a fixed design a sample size of n = 128 would be required to obtain a power
of 1− β = 0.8. However, it is important to emphasize that in practice the true variance
and the respective true fixed design sample size are not known. Therefore, by varying
the internal pilot study over a wide range we include the cases in the simulation study
in which the internal pilot study sample size is specified based on a variance deviating
from the true variance. Moreover, as Table 3 highlights, during the simulation study
particular emphasis is put on the performance of the sample size re-estimation procedure
when the internal pilot study sample size n1 and the effective sample size change. The
shape parameter a and rate parameter b of the prior density pσ2(·) are chosen based on
the effective sample size ESS and the expected value of the prior distribution. The shape
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Table 3: Scenarios for the Monte Carlo simulation study.
Parameter Value
One-sided significance level α 0.025
Target power 1− β 0.8
Margin δ∗ in the alternative 0.5
True variance σ2 1
Internal pilot study size n1 10, 20, . . . , 100
Sample size ratio k 1
Expected value of prior pσ2(·) (no prior-data conflict) 1
Expected value of prior pσ2(·) (prior-data conflict) 0.49
Effective sample size ESS of prior pσ2(·) 6, 25, 50
parameter is half of the effective sample size: a = ESS/2. Let σ2mean denote the expected
value of the prior distribution of the variance. Since the prior of the variance has an
inverse Gamma distribution, the expected value is given by σ2mean = b/(a− 1). Thus, the
rate parameter is determined to be b = σ2mean(ESS/2− 1). The expected value σ2mean of
the prior distribution is set to one to model the settings with no prior-data conflict. On
the other hand, to model a prior-data conflict, the expected value of the prior distribution
is set to σ2mean = 0.49. Each simulated power in this section is based on 50 000 Monte
Carlo replications which corresponds to a simulation error of less than 0.0018 for a simu-
lated power of 0.8. In the following the results of the Monte Carlo simulation study are
presented for the scenarios without prior-data conflict listed in Table 3. Figure 3 plots the
power of Student’s t-test against the internal pilot study sample size n1 for the different
sample size re-estimation procedures. Figure 3 shows, if no prior-data conflict is present,
incorporating external data into the sample size re-estimation results in a power closer to
the nominal level compared to the traditional sample size re-estimation approach, except
for a small prior effective sample size of ESS = 6. A sample size re-estimation based
on the posterior mean σˆ21,mean leads to better results than the re-estimation based on the
posterior median σˆ21,med. This is due to the equality of the prior mean and the true vari-
ance as well as the fact that the prior median is slightly smaller than the prior mean for
the considered scenarios. Moreover, the larger the prior effective sample size, the smaller
is the internal pilot study sample size required to reach to the nominal power level. In
Figure 4 the distribution of the final sample size nˆfinal, depicted by the median and the
range between the 10% and 90% percentiles, is compared between the traditional sample
size re-estimation procedure and the procedure incorporating prior information. We do
not present the results for the re-estimation procedure based on the posterior median
since the results are qualitatively the same as for the procedure based on the posterior
mean. Figure 4 shows that the distribution of the final sample size is positively skewed for
both sample size re-estimation procedures. Moreover, even incorporating prior informa-
tion with a small prior effective sample size of ESS = 6 into the sample size re-estimation
results in a smaller variability of the final sample size. The variability of the final sample
size obtained with the sample size re-estimation procedure incorporating prior information
decreases as the prior effective sample size increases. The difference in variability between
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Figure 3: Power of the different sample size re-estimation procedures for prior effective
sample sizes of ESS = 6, 25, 50. The expected value of the prior information is identical
to the true variance σ2 = 1, thus, no prior-data conflict is present. The horizontal grey
line depicts the nominal power of 80%.
the sample size re-estimation procedures with and without incorporated prior informa-
tion decreases as the internal pilot study sample size increases since the larger the internal
pilot study sample size, the smaller the effect of the prior on the posterior distribution.
Additionally, we studied the type I error rate of the proposed sample size re-estimation
procedure incorporating prior information on the variance and compared the results with
the type I error rate of the sample size re-estimation procedure using the unblinded pooled
sample variance. The results are presented in Section 1 of the Supplementary Material.
The type I error rate of the proposed sample size re-estimation procedure incorporating
prior information has a type I error inflation similar to the unblinded sample size re-
estimation procedure based on the pooled sample variance for small prior effective sample
sizes. Moreover, the type I error rate of the proposed sample size re-estimation procedure
incorporating prior information decreases and converges against the nominal level as the
prior effective sample size increases. In conclusion, incorporating prior information into
the sample size re-estimation is beneficial when no prior-data conflict is present.
Next, we study how a prior-data conflict affects the performance of the sample size
re-estimation procedure when the prior-data is incorporated into the sample size re-
estimation. Thereto, we still consider a true variance of one, σ2 = 1, but now the
parameters of the prior density pσ2(·) are chosen such that the prior distribution has
an expected value of σ2mean = 0.49. The results of the corresponding Monte Carlo sim-
ulation study are presented in Figure 5. Figure 5 shows that sample size re-estimation
incorporating a prior which conflicts with the actual data results in underpowered trials
if the prior distribution has a mean or median smaller than the true variance. Even for a
small prior effective sample size of ESS = 15, large internal pilot studies cannot resolve
the prior-data conflict. The underpowering increases as the effective sample size increases
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Figure 4: Median and percentiles (10% and 90%) of the final sample size. The expected
value of the prior information is identical to the true variance σ2 = 1, thus, no prior-data
conflict is present. The horizontal grey line depicts the fixed design sample size of n = 128.
but decreases as the internal pilot study sample size increases. If the prior distribution
would have a mean or median larger than the true variance, the sample size re-estimation
incorporating prior information would overpower the clinical trial. Thus, the sample size
re-estimation procedure incorporating prior information using the MAP prior does not
meet the basic performance requirement when the prior-data is in conflict with the vari-
ance of the ongoing clinical trial.
For the last part of this simulation study, we robustify the MAP prior as introduced
above and assess whether the corresponding sample size re-estimation procedure incor-
porating prior information is robust against prior-data conflicts. We assume that the
MAP prior pσ2(·) on the variance has an expected value of σ2mean = 0.49 while the true
variance is σ2 = 1. For the robustification we mix the MAP prior pσ2(·) with a vague
prior pV (·) which follows an inverse Gamma distribution with shape parameter a = 2 and
rate parameter b = 1. The vague prior has a prior effective sample size of ESS = 4 and
its expected value is equal to one, i.e. the same as the true variance. Thus, this choice
of vague prior corresponds to an idealized setting which aims to emphasize what can be
achieved concerning power control by robustifying the MAP prior. The robustified MAP
prior of the precision is given by
wR Gamma(2, 1) + (1− wR) Gamma (ESS/2, 0.49(ESS/2− 1)) . (3)
Moreover, the prior probability of a prior-data conflict, wR, is varied within the simulation
study between 0.05 and 0.95. A small value of wR corresponds to a small prior probability
of a prior-data conflict. Here, we focus on the results for an internal pilot study size of
n1 = 60 which corresponds to about half the sample size required in the fixed sample
design. The effective sample size of the informative part of the robustified prior, pσ2(·),
is set to ESS = 25, 50. The results of the power simulation are shown in Figure 6. More
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Figure 5: Power of the different sample size re-estimation procedures for prior effective
sample sizes of ESS = 6, 15, 25, 50. The prior is in conflict with the data in the sense that
the prior has an expected value of 0.49 while the true variance is σ2 = 1. The horizontal
grey line depicts the nominal power of 80%.
detailed simulation results in which the internal pilot study size is varied too and more
effective sample sizes are considered are shown in the Supplementary Material. Figure
6 shows that the larger the prior probability of a prior-data conflict, the less does the
prior-data conflict affect the power of the final analysis after sample size re-estimation.
However, Figure 6 also shows that the prior probability wR for a data conflict has to be
very close to one in the case of a prior-data conflict to mitigate the effects of a prior-data
conflict on the power. Moreover, an increase of the prior probability wR also reduces the
benefits of incorporating prior information into the sample size re-estimation when no
prior-data conflict is present as the results shown in the Supplementary Material high-
light.
Robustifying the MAP prior does not result in the desired power of the sample size
re-estimation procedure for the case of a prior-data conflict because the information from
the internal pilot study cannot appropriately discount the prior information. We will
illustrate the inability of the internal pilot study to discount incorrect prior information
further in the following. Thereto, we assume an observed pooled variance of one from the
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Figure 6: Power of the different sample size re-estimation procedures when the prior is
robustified and a prior-data conflict is present. The sample size of the internal pilot study
is n1 = 60. The horizontal grey line depicts the nominal power of 80%.
internal pilot study, i.e. σˆ21,pool = 1. The prior information on the variance is the same
as the mixture in Formula (3). In Figure 7 the posterior mean of the variance is plotted
against the prior probability wR of a prior-data conflict for the prior effective sample sizes
ESS = 25, 50 as well as the internal pilot study sizes n1 = 25, 50, 75. Figure 7 shows only
a large prior probability wR of a data conflict results in discounted prior information. The
larger the internal pilot study sample size, the more the prior information is discounted
for a fixed prior probability wR. Moreover, a larger prior effective sample size can also
be beneficial in detecting a prior-data conflict. However, for the considered practically
relevant effective sample sizes and internal pilot study sizes the prior information cannot
be discounted enough to not reduce the power of the sample size re-estimation procedure
incorporating prior information in the case of a prior-data conflict. As for the case of
no prior-data conflict, we also studied the performance of the proposed sample size re-
estimation procedure concerning the type I error rate when a prior-data conflict is present
and the MAP prior is robustified. As highlighted in Section 1 of the Supplementary Mate-
rial, incorporating robustified prior information into the sample size re-estimation results
in a type I error inflation similar to the case of unblinded sample size re-estimation based
on the pooled variance estimator.
Concluding, incorporating prior information into the sample size re-estimation results
in a power closer to the target power compared to the sample size re-estimation based on
the pooled variance estimator in the case of no prior-data conflict. Moreover, the variabil-
ity of the final sample size also decreases when correct prior information are incorporated
into the sample size re-estimation. However, when the prior information conflicts with
the data from the internal pilot study, incorporating prior information into the sample
size re-estimation leads to under- or overpowered clinical trials. The adverse influence of a
prior-data conflict can be limited, but not corrected, by robustifying the prior information
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Figure 7: Posterior mean of the variance when the pooled variance estimator from the
internal pilot study is equal to one, σˆ21,pool = 1.
which, however, reduces the benefit of incorporating prior information into the sample
size re-estimation in the case of no prior-data conflict.
6 Blinded sample size re-estimation
In this section we discuss various ways of incorporating prior information into the blinded
sample size re-estimation and we outline why the resulting procedures face the same
obstacles as the unblinded procedures in the case of a prior-data conflict. The one-sample
variance estimator, which estimates the unknown variance by the sample variance of
the blinded data, is the recommended method for blinded sample size re-estimation in
two-arm trials with continuous data. [25] In contrast to sample size re-estimation based
on the unbiased pooled sample variance, sample size re-estimation based on one-sample
variance estimator meets the target power due to overestimating the outcome variance.
The relationship between the one-sample variance estimator σˆ2OS and the pooled sample
variance can be illustrated by the following equation [34]
σˆ2OS =
n1 − 2
n1 − 1 σˆ
2
pool +
n1Tn1C
n1(n1 − 1)
(
X¯1T − X¯1C
)2
.
Since simply replacing the pooled variance estimator with the one-sample variance estima-
tor resulted in the desired properties of the sample size re-estimation procedure without
prior information, it seems natural to proceed similar when incorporating prior informa-
tion into the sample size re-estimation. Thus, when updating the prior information on
the variance the pooled sample variance could be replaced by the one-sample variance
estimator. Doing so increases the power of the sample size re-estimation procedure incor-
porating prior information. In simulations not presented here we observed that in the case
of a prior-data conflict the power increase is small compared to the deviations from the
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target power and that the prior information are not discounted enough to actually obtain
a suitable procedure for incorporating prior information into the sample size re-estimation
in the case of a prior-data conflict.
An alternative method for blinded sample size re-estimation in two-arm trials with a
randomized block design is based on the Xing-Ganju variance estimator which estimates
the outcome variance blinded based on the block sums. [35] Sample size re-estimation in-
corporating prior information can be extended to not require unblinding by focusing on
the likelihood of the block sums when updating the prior information. In more detail, let
b be the number of randomized blocks and let m be the number of observations within
each block. For the sake of simplicity, we assume equal allocation between treatment arms
within each block. Conditioned on the means µT and µC and the variance σ
2, the block
sums Ti, i = 1, . . . , b, are normally distributed,
Ti|µT , µC, σ2 ∼ N
(
0.5m(µT + µC), mσ
2
)
.
Thus, Si = Ti/
√
m follows conditionally a normal distribution with mean 0.5
√
m(µT+µC)
and variance σ2. In Section 3 we considered improper uniform priors for the means. Under
this assumption, the prior for the sum of means is also an improper uniform prior. The
formulas for updating a Gamma mixture prior for the precision can be easily adapted
from Section 3 by using the Xing-Ganju estimator
σˆ2XG =
1
b− 1
b∑
i=1
(Si − S¯·)2
instead of the pooled variance estimator and noting that the degrees of freedom are b− 1
instead of n1 − 2. That being said, the similarity of the models also implies that the
performance of the resulting sample size re-estimation procedures incorporating prior in-
formation will be very similar to the case of the unblinded sample size re-estimation with
prior information. The lower number of degrees of freedom of the Xing-Ganju variance
estimator further reduces the ability to discount prior information in the case of a prior-
data conflict, too. Thus, blinded sample size re-estimation incorporating prior information
based on the Xing-Ganju variance estimator will not achieve the target power in the case
of a prior-data conflict.
The blinded data from the internal pilot study follow a mixture of two normal distri-
butions. Therefore, it has been studied to estimate the variance for the blinded sample
size re-estimation using the expectation-maximization (EM) algorithm. [34,36,37] However,
the variance estimator from the EM algorithm is biased downwards resulting in a sample
size re-estimation procedure underpowering clinical trials. When updating the prior in-
formation on the variance after the internal pilot study using the likelihood of a mixture
of normal distributions, similar effects can be observed. The posterior distribution for
the variance has a mean and median smaller than the pooled variance. Thus, considering
those location parameters in the sample size re-estimation does also result in underpow-
ering the clinical trial in the case of a prior-data conflict.
Concluding, prior information can easily be incorporated into the blinded sample size
re-estimation. However, similar to the unblinded sample size re-estimation incorporating
prior information, in the case of a prior-data conflict the prior information cannot be dis-
counted enough to ensure that the resulting sample size re-estimation procedure results
in a clinical trial meeting the target power.
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7 Discussion
In this manuscript we studied various methods for incorporating prior information on the
nuisance parameter into the nuisance parameter based sample size re-estimation. The
prior information was given as an MAP prior which is obtained through a meta-analysis
of variances from historical clinical trials using a Bayesian hierarchical model. In the
case of no prior-data conflict, that is when the prior mean corresponds to the sample
variance of the ongoing clinical trial, incorporating prior information into the sample size
re-estimation decreases the variability of the final sample size compared to the unblinded
sample size re-estimation based on the pooled sample variance. Moreover, in contrast to
the unblinded nuisance parameter based sample size re-estimation procedure, the sample
size re-estimation procedure incorporating prior information on the nuisance parameter
meets the nominal power when the prior information is correct. However, the sample size
re-estimation approach incorporating prior information is not robust concerning prior-
data conflicts in which case it leads to under- or overpowered clinical trials. Robustifying
the MAP prior improves the performance of the sample size re-estimation approach in-
corporating prior information, however, not to the point where the clinical trials are not
under- or overpowered. This is due to the internal pilot studies not containing enough
information to sufficiently discount the misspecified prior information. The performance
of the nuisance parameter based sample size re-estimation procedure incorporating prior
information was primarily studied for unblinded data even though the use of blinded
data is generally recommended when the sample size is adjusted based on a nuisance pa-
rameter estimate. That being said, we proposed several approaches to incorporate prior
information into the blinded sample size re-estimation and we exemplified that the re-
sulting blinded sample size re-estimation procedures incorporating prior information do
not meet the target power either when a prior-data conflict is present. Concluding, incor-
porating prior information on the nuisance parameter into the nuisance parameter based
sample size re-estimation can be beneficial in the sense that it reduces the variability of
the final sample size compared to the sample size re-estimation without prior information.
However, incorporating prior information on the nuisance parameter into the sample size
re-estimation also bears the risk of resulting in an under- or overpowered clinical trial
when a prior-data conflict is present. The severity of missing the target power in the
case of a prior-data conflict depends on the size of the prior-data conflict, on the prior
effective sample size, and on the internal pilot study sample size. Thus, the decision
whether to incorporate prior information on the nuisance parameter into the sample size
re-estimation can only be made on a case-to-case basis after carefully weighting the risks
with the potential benefits. It is also worth emphasizing that for the studied clinical
trial setting the traditional nuisance parameter based sample size re-estimation using the
one-sample variance estimator does not bear the risk of missing the target power.
The sample size re-estimation procedure incorporating prior information inflates the
type I error rate in a similar magnitude as the unblinded sample size re-estimation pro-
cedure based on the pooled sample variance. However, strategies for controlling the type
I error inflation have been proposed in the literature. [38,39]
In this manuscript we robustified the MAP prior from historical data by mixing it
with a vague prior. The prior probability wR of a prior-data conflict is prespecified, i.e.
it is not a random variable and does not depend on the data which is used to update
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the prior distribution, as it was proposed by Schmidli et al. [3] It should be noted that
the weight wR will be different in the posterior distribution. For example, if there is a
prior-data conflict, this weight will be lower.
Hartley studied blinded sample size re-estimation for normal data and concluded that
incorporating prior information into the blinded sample size re-estimation is generally
recommended. [15] It is worth highlighting the differences between Hartley’s publication
and our manuscript since we draw a different conclusion. In Hartley’s publication, prior
information on both the variance and the effect are incorporated into the sample size re-
estimation which selects the final sample size based on a predictive power. In contrast, we
did not consider uncertainty in the effect size and we studied the setting where the final
sample size is determined based on the sample size formula for Student’s t-test as it is
common in nuisance parameter based sample size re-estimation for a frequentist analysis
at the end of the clinical trial. Moreover, in this manuscript we focused on the overar-
ching approach of both summarizing the prior information based on the MAP approach
and incorporating the gathered prior information into the nuisance parameter based sam-
ple size re-estimation. We also extensively studied the case of prior-data conflicts which
eventually lead to our conclusion that the decision to incorporate prior information on the
nuisance parameter into the sample size re-estimation has to be made on a case-to-case
basis.
The focus of this manuscript was nuisance parameter based sample size re-estimation in
the case of a two-arm parallel group superiority trial with normally distributed outcomes.
Nuisance parameter based sample size re-estimation has been proposed for other designs
such as designs with more than two treatment arms or designs with count data. [40,41]
The performance of the nuisance parameter based sample size re-estimation procedures
incorporating prior information in these designs might differ due to larger internal pilot
studies or endpoints for which prior-data conflicts can be detected easier.
We focused on nuisance parameter based the sample size re-estimation. Others have
proposed to adjust the sample size of a clinical trial based on treatment effect estimates. [42]
Additionally, the use of Bayesian approaches has already be advocated for monitoring
group sequential designs. [43] In future research, incorporating prior information about the
effect into the sample size re-estimation should be studied. Moreover, while we presented
a re-estimation approach which adjusts the sample size by plugging in a Bayes point esti-
mator into the sample size formula, other rules for selecting the final sample size could be
chosen. For instance, decision theoretic methods could be used to derive possibly better
rules for the sample size re-estimation. [44]
The simulation and calculations presented in this manuscript were performed using
the R language. [45] To reproduce the results presented in this manuscript, the respective
code has been made available through the R package varmap. [46]
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